Studies proposed for the first year of the Program Project Grant in clinical projects 3-5 will generate over 350 marrow, peripheral blood and cord blood samples (Tables 1,2,3). These samples will be distributed among the laboratories of the project leaders, core leaders and collaborators for assessment of phenotype, progenitor content, retroviral marking and evidence of contamination with malignant cells when relevant. The Sample Procurement Core (Core C) will support a centralized effort to procure and distribute samples generated by experiments proposed in Projects 3-5 to the appropriate research laboratories. Sample Procurement Core personnel will monitor patient entry into clinical trials and obtain required samples in a proactive fashion. Samples will be logged, and minimal processing (e.g., preparation of mononuclear cell fraction) performed under standard conditions. When appropriate, samples will be subjected to rate controlled freezing and stored in liquid nitrogen in a central facility under the supervision of Sample procurement Core Personnel. Either fresh or frozen samples will be delivered to the appropriate laboratories. These efforts will be supported by a core leader (Dr. Jeffrey Miller, M.D.) who is also an active investigator and research project leader (Project 2). The Sample procurement Core will serve as a resource for the entire program project which provides organization, integration, quality control and oversight coordinated by a single responsible core leader.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA065493-02
Application #
5209379
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
2
Fiscal Year
1996
Total Cost
Indirect Cost
Taraseviciute, Agne; Tkachev, Victor; Ponce, Rafael et al. (2018) Chimeric Antigen Receptor T Cell-Mediated Neurotoxicity in Nonhuman Primates. Cancer Discov 8:750-763
Felices, Martin; Lenvik, Alexander J; McElmurry, Ron et al. (2018) Continuous treatment with IL-15 exhausts human NK cells via a metabolic defect. JCI Insight 3:
Sarhan, Dhifaf; Hippen, Keli L; Lemire, Amanda et al. (2018) Adaptive NK Cells Resist Regulatory T-cell Suppression Driven by IL37. Cancer Immunol Res 6:766-775
Williams, Robin L; Cooley, Sarah; Bachanova, Veronika et al. (2018) Recipient T Cell Exhaustion and Successful Adoptive Transfer of Haploidentical Natural Killer Cells. Biol Blood Marrow Transplant 24:618-622
Don Yun, Hyun; Felices, Martin; Vallera, Daniel A et al. (2018) Trispecific killer engager CD16xIL15xCD33 potently induces NK cell activation and cytotoxicity against neoplastic mast cells. Blood Adv 2:1580-1584
Hippen, Keli L; Loschi, Michael; Nicholls, Jemma et al. (2018) Effects of MicroRNA on Regulatory T Cells and Implications for Adoptive Cellular Therapy to Ameliorate Graft-versus-Host Disease. Front Immunol 9:57
Pennell, Christopher A; Barnum, Jessie L; McDonald-Hyman, Cameron S et al. (2018) Human CD19-Targeted Mouse T Cells Induce B Cell Aplasia and Toxicity in Human CD19 Transgenic Mice. Mol Ther 26:1423-1434
Williams, Shelly M; Sumstad, Darin; Kadidlo, Diane et al. (2018) Clinical-scale production of cGMP compliant CD3/CD19 cell-depleted NK cells in the evolution of NK cell immunotherapy at a single institution. Transfusion 58:1458-1467
Mathew, Nimitha R; Baumgartner, Francis; Braun, Lukas et al. (2018) Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells. Nat Med 24:282-291
Romee, Rizwan; Cooley, Sarah; Berrien-Elliott, Melissa M et al. (2018) First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation. Blood 131:2515-2527

Showing the most recent 10 out of 395 publications